

IPU/1625  
PATENT


Attorney Docket No. 00769-07

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Applicant:	Milton L. Brown	}	Customer No.	34444
Serial No.	10/511,666	}	Art Unit:	1625
Filed:	October 18, 2004	}	Examiner:	Unknown
Title:	Novel Sodium Channel Blockers			

Certificate of Mailing Under 37 CFR §1.8

I hereby certify that this correspondence is being deposited with the United States Postal Service using First Class Service under 37 C.F.R. § 1.8 on the date indicated below and is addressed to Commissioner for Patents, PO Box 1450, Alexandria, VA 22313-1450.

Date: March 15, 2006  
Sue Ann Carr**TRANSMITTAL OF SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 C.F.R. 1.97 (b)(3)**

Commissioner for Patents  
PO Box 1450  
Alexandria, VA 22313-1450


Sir:

Submitted herewith please find a supplemental Information Disclosure Statement for the above-identified application, consisting of Form PTO/SB/08A and ten (10) copies of foreign patents and Form PTO/SB/08B, and fourteen (14) copies of references. The Information Disclosure Statement is being filed before the mailing date of a first Office Action on the merits per 37 C.F.R. 1.97(b)(3).

Applicants respectfully submit that the filing of this supplemental Information Disclosure Statement is not a representation that a prior art search was conducted or that the information cited is material to the patentability of the invention as defined in 37 CFR § 1.56, or that any cited document is prior art. Applicants request that the Examiner consider the references, determine their relevance to the present application, if any, and list the references on the face of any patent which may issue from the present application. Applicants further request that an initialed copy of Forms PTO/SB/08A and PTO/SB/08B be returned to applicants.

No fees are believed to be due for this submission. If this belief is in error, the Commissioner is hereby authorized to charge any fees due for this submission to Deposit Account No. 50-0423, as well as credit any refunds.

Respectfully submitted,



Rodney L. Sparks  
Registration No. 53,625

March 15, 2006

University of Virginia Patent Foundation  
250 West Main Street, Suite 300  
Charlottesville, VA 22902  
Telephone: (434) 243-2870  
Fax: (434) 924-2493

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

Sheet 1 of 2**Complete if Known**

Application Number	10/511,666
Filing Date	October 18, 2004
First Named Inventor	Milton L. Brown
Art Unit	1625
Examiner Name	Unknown
Attorney Docket Number	00769-07

**U. S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number Number-Kind Code <sup>2</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	1	US- 5,463,125	10/31/2005	Guillermo C. Sandoval et al.	Entire Document
	2	US- 2,366,221	01/02/1945	James J. Spurlock	Entire Document
	3	US- 2,256,231	10/17/1950	Henry R. Henze	Entire Document
	4	US- 2002156016 A1	10/24/2002	Gerald Minuk	Entire Document
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			
		US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
	5	EP 0552631 A1	07/28/1993	Bayer AG	Entire Document	
	6	EP 0076957 A1	04/20/1983	Bayer AG	Entire Document	
	7	WO 99/41229 A1	08/19/1999	Guillermo Sandoval	Entire Document	
	8	SU 447401	10/25/1974	Perm Pharm. Inst.	Entire Document	
	9	GB 980250	1/13/1965	Innothera	Entire Document	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

*(Use as many sheets as necessary)*

Sheet	2	of	2
-------	---	----	---

**Complete if Known**

Application Number	10/511,666
Filing Date	October 18, 2004
First Named Inventor	Milton L. Brown
Art Unit	1625
Examiner Name	Unknown
Attorney Docket Number	00769-07

## U. S. PATENT DOCUMENTS

[illegible]

## FOREIGN PATENT DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document			Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup>	Number <sup>4</sup>	Kind Code <sup>5</sup> (if known)				
	10	EP	0006407	A1	1/9/1980	Nippon Zoki Pharm.	Entire Document	
	11	WO	02/083133	A1	10/24/2002	Univ of Va Patent Found.	Entire Document	
	12	GB	1566171		4/30/1980	Pfizer, Inc.	Entire Document	
	13	EP	0115133	A1	8/8/1984	Pfizer, Inc.	Entire Document	
	14	WO	01/45704	A1	6/28/2001	Merck & Co.	Entire Document	


Examiner Signature	Date Considered
-----------------------	--------------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. 1 Applicant's unique citation designation number (optional). 2 See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. 3 Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). 4 For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. 5 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. 6 Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

*If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.*

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.



Substitute for form 1449B/PTO

# INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(Use as many sheets as necessary)

Sheet

1

of

2

## Complete if Known

Application Number	10/511,666
Filing Date	October 18, 2004
First Named Inventor	Milton L. Brown
Art Unit	1625
Examiner Name	Unknown
Attorney Docket Number	00769-07

## NON PATENT LITERATURE DOCUMENTS

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	A	ABDUL, M. et al., (2001), "Inhibition by Anticonvulsants of Prostate-specific Antigen and Interleukin-6 Secretion by Human Prostate Cancer Cells," Anticancer Research, vol. 21, pp. 2045-2048.	
	B	MEZA-TOLEDO, S.E. et al., (1995), "Stereoselective Anticonvulsant Activity of the Enantiomers of (+-)-2-Hydroxy-2-phenylbutyramide," Arzneimittel Forschung. Drug Research, vol. 45, pp. 756-759.	
	C	MEZA-TOLEDO, S.E. et al., (1990), "A New Homologous Series of Anticonvulsants: Phenyl Alcohol Amides," Arzneimittel Forschung. Drug Research, vol. 40, pp. 1289-1291.	
	D	WILIMOWSKI, M. et al., (1970), "Pharmacologic Properties of Derivatives of 3-Phenyl-3-Hydroxyglutaric Acid," Archivum Immunologiae et Therapiae Experimentalis, vol. 18, pp.270-279.	
	E	BARRIO, J. et al., (1971), "5-Cyclohexylmethyl-5-arylhydantoins," Journal of Medicinal Chemistry, vol. 14, no. 9, p. 898.	
	F	BROWN, M.L. et al., (1999), "Comparative Molecular Field Analysis of Hydantoin Binding to the Neuronal Voltage-Dependent Sodium Channel," J. Med. Chem., vol. 42, pp. 1537-1545.	
	G	KNABE, J. et al., (1997), "Razemate und Enantiomere basisch substituierter 5-Phenylhydantoine, Synthese und antiarrhythmische Wirkung, Racemates and enantiomers of basic substituted 5-phenylhydantoins, synthesis and antiarrhythmic activity," Pharmazie, Die, Gopvi Verlag, Eschborn, De, vol. 52, pp. 912-919.	
	H	CASAGRANDE, C. et al., (1974), "Synthesis and antiarrhythmic activity of 5,5-disubstituted-3-aminoalkylhydantoins and some heterocyclic and noncyclic analogues," Farmaco, Edizione Scientifica, Societa Chimica Italiana, Pavia IT, vol. 29, no. 10, pp. 757-785.	
	I	BROUILLETTE, W.J. et al., (1990), "Sodium channel binding and anticonvulsant activities of hydantoins containing conformationally constrained 5-phenyl substituents," J. of Pharmaceutical Sciences, Am. Pharmaceutical Assoc. Washington, US, vol. 79, no. 10, pp. 871-874.	
	J	KADAM, A.N. et al., (1978), "Synthesis of gamma-(5-arylhydantoin-5)-butyric acids," J. of the Indian Chemical Society, Calcutta, IN, vol. 51, no. 1, pp. 107-108.	

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(Use as many sheets as necessary)

**Complete if Known**

Application Number	10/511,666
Filing Date	October 18, 2004
First Named Inventor	Milton L. Brown
Art Unit	1625
Examiner Name	Unknown
Attorney Docket Number	00769-07

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	K	DESPHANDE, R.N. et al., (1970), "Synthesis of Hydantoins of Pharmacological Interest," Indian Journal of Chemistry, Section B: Organic, Incl. Medicinal, Publications & Informations Directorate, New Delhi, IN, vol. 8, no. 11, pp. 1043-1044.	
	L	GALVEZ, E. et al., (1983), "Synthesis and Structural Study of Cyclopentane, Indene and Fluorene Spiro-derivatives," Journal of Heterocyclic Chemistry, Heterocorporation. Provo, US, vol. 20, no. 1, pp. 13-16.	
	M	SARGES, R. et al., (1987), "Spiro Hydantoin Aldose Redutase Inhibitors," Journal of Medicinal Chemistry, vol. 31, no. 1, pp. 230-242.	
	N	DUPRIEST, M.T. et al., (1991), "Spiro[fluoreneisothiazolidin]one Dioxides: New Aldose Redutase and L-Hexonate dehydrogenase Inhibitors," Journal of Medicinal Chemistry, vol. 34, no. 11, pp. 3229-3234.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

1 Applicant's unique citation designation number (optional). 2 Applicant is to place a check mark here if English language Translation is attached. This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 and select option 2.